0.2249

0.85% +0.0019

After Hours: .2222 -0.0027 -1.20%

60 Degrees Pharmaceuticals Inc (SXTP)

Overview News Price History Why SXTP Down? Discussions Forecast

60 Degrees Pharmaceuticals Inc stock is currently priced at $0.2249, with a 24-hour trading volume of 1.27M. It has seen a +0.85% increased in the last 24 hours and a -10.68% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.2192 pivot point. If it approaches the $0.2285 resistance level, significant changes may occur.

Previous Close:

$0.223

Open:

$0.232

24h Volume:

1.27M

Market Cap:

$2.60M

Revenue:

$90,700

Net Income/Loss:

$-3.43M

P/E Ratio:

-0.1383

EPS:

-1.6266

Net Cash Flow:

$-4.65M

1W Performance:

-0.04%

1M Performance:

-10.68%

6M Performance:

-67.64%

1Y Performance:

+0.00%

1D Range:

$0.22

$0.2545

52W Range:

$0.2011

$1.53

60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile

Name

60 Degrees Pharmaceuticals Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

202-327-5422

Address

1025 Connecticut Avenue NW, Suite 1000, Washington

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SXTP's Discussions on Twitter

60 Degrees Pharmaceuticals Inc Stock (SXTP) Latest News

Financial Snapshot: Analyzing 60 Degrees Pharmaceuticals Inc (SXTP)'s Key Ratio Metrics – DWinneX - The Dwinnex

The Dwinnex

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results - GlobeNewswire

GlobeNewswire

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

GlobeNewswire Inc.

YMCA offers free facilities access in Edmonton to evacuees fleeing Fort McMurray wildfire - Yahoo Finance Australia

Yahoo Finance Australia

Tamarack Valley Energy Ltd. Releases 2024 Sustainability Report - Yahoo Canada Finance

Yahoo Canada Finance

Tamarack Valley Energy Ltd. Reports Voting Results of Annual General Meeting of Shareholders - Yahoo Canada Finance

Yahoo Canada Finance

60 Degrees Pharmaceuticals Inc Stock (SXTP) Financials Data

60 Degrees Pharmaceuticals Inc (SXTP) Revenue 2024

SXTP reported a revenue (TTM) of $90.70 thousand for the quarter ending September 30, 2023, a -68.70% decline year-over-year.

60 Degrees Pharmaceuticals Inc (SXTP) Net Income 2024

SXTP net income (TTM) was -$3.43 million for the quarter ending September 30, 2023, a +41.57% increase year-over-year.

60 Degrees Pharmaceuticals Inc (SXTP) Cash Flow 2024

SXTP recorded a free cash flow (TTM) of -$4.65 million for the quarter ending September 30, 2023.

60 Degrees Pharmaceuticals Inc (SXTP) Earnings per Share 2024

SXTP earnings per share (TTM) was -$0.5967 for the quarter ending September 30, 2023, a +43.36% growth year-over-year.

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.